Tian Zhang

Positions:

Assistant Professor of Medicine

Medicine, Medical Oncology
School of Medicine

Member of the Duke Cancer Institute

Duke Cancer Institute
School of Medicine

Education:

M.D. 2009

Harvard Medical School

M.H.S. 2019

Duke University School of Medicine

Internal Medicine Residency, Medicine

Duke University School of Medicine

Fellowship in Hematology-Oncology, Medicine

Duke University School of Medicine

Grants:

Duke-UNC-Wash U Partnership for Early Phase Clinical Trials in Cancer

Administered By
Medicine, Medical Oncology
Awarded By
National Institutes of Health
Role
Significant Contributor
Start Date
End Date

CTC-Immune Checkpoints

Administered By
Duke Cancer Institute
Role
Co-Principal Investigator
Start Date
End Date

Conditional lethality of copper and disulfiram as a therapeutic modality for prostate cancer

Administered By
Medicine, Medical Oncology
Awarded By
V Foundation for Cancer Research
Role
Principal Investigator
Start Date
End Date

A Phase III, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Pembrolizumab (MK-3475) as Monotherapy in the Adjuvant Treatment of Renal Cell Carcinoma Post Nephrectomy (KEYNOTE-564)

Administered By
Duke Cancer Institute
Role
Principal Investigator
Start Date
End Date

A Salvage Trial of AR Inhibition with ADT and Apalutamide with Docetaxel followed by Radiation Therapy in Men with PSA Recurrent Prostate Cancer after Radical Prostatectomy (¿STARTAR¿)

Administered By
Duke Cancer Institute
Role
Principal Investigator
Start Date
End Date

Publications:

Longitudinal multiplex cytokine analysis for patients (pts) with metastatic renalcell carcinoma (mRCC) treated with ipilimumab/nivolumab (I plus N).

Authors
Zhang, T; Wu, Y; Agarwal, A; Starr, MD; Reyes-Martinez, M; Anand, M; Runyambo, D; Harrison, MR; Armstrong, AJ; George, DJ; Nixon, AB
MLA Citation
Zhang, Tian, et al. “Longitudinal multiplex cytokine analysis for patients (pts) with metastatic renalcell carcinoma (mRCC) treated with ipilimumab/nivolumab (I plus N).Journal of Clinical Oncology, vol. 38, no. 6, AMER SOC CLINICAL ONCOLOGY, 2020.
URI
https://scholars.duke.edu/individual/pub1441188
Source
wos
Published In
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
Volume
38
Published Date

Investigating the role of the gastrointestinal microbiome in response to immune checkpoint inhibitors (ICIs) among patients (pts) with metastatic renal cell carcinoma (mRCC)

Authors
Agarwal, A; Modliszewski, J; Davey, L; Reyes-Martinez, M; Runyambo, D; Corcoran, D; Dressman, H; George, DJ; Valdivia, R; Armstrong, AJ; Zhang, T
MLA Citation
URI
https://scholars.duke.edu/individual/pub1441328
Source
wos
Published In
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
Volume
38
Published Date

Multicenter retrospective analysis of patients with metastatic renal cell carcinoma (mRCC) and bone metastases treated with ipilimumab and nivolumab

Authors
Desai, K; Brown, LC; Wei, W; Allman, KD; Martin, A; Wood, LS; Gupta, S; Gilligan, TD; Garcia, JA; Kao, C; Kinsey, EN; Healy, P; Kephart, J; Harrison, MR; Ramalingam, S; Armstrong, AJ; George, DJ; Rini, BI; Zhang, T; Ornstein, MC
MLA Citation
Desai, Kunal, et al. “Multicenter retrospective analysis of patients with metastatic renal cell carcinoma (mRCC) and bone metastases treated with ipilimumab and nivolumab.” Journal of Clinical Oncology, vol. 38, no. 6, AMER SOC CLINICAL ONCOLOGY, 2020.
URI
https://scholars.duke.edu/individual/pub1441329
Source
wos
Published In
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
Volume
38
Published Date

A multicenter retrospective study to evaluate real-world clinical outcomes in patients with metastatic renal cell carcinoma (mRCC) and brain metastasis treated with ipilimumab and nivolumab

Authors
Brown, LC; Desai, K; Kao, C; Kinsey, EN; Healy, P; Kephart, J; Harrison, MR; Ramalingam, S; Armstrong, AJ; George, DJ; Martin, A; Allman, KD; Wood, LS; Wei, W; Garcia, JA; Gilligan, TD; Gupta, S; Rini, BI; Ornstein, MC; Zhang, T
MLA Citation
URI
https://scholars.duke.edu/individual/pub1441330
Source
wos
Published In
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
Volume
38
Published Date

Patient-reported outcomes on treatment-related side effects in renal cell carcinoma

Authors
Battle, D; Rathmell, WK; Jonasch, E; Msaouel, P; Stern, AP; Zhang, T; George, DJ; Staehler, MD
MLA Citation
Battle, Dena, et al. “Patient-reported outcomes on treatment-related side effects in renal cell carcinoma.” Journal of Clinical Oncology, vol. 38, no. 6, AMER SOC CLINICAL ONCOLOGY, 2020.
URI
https://scholars.duke.edu/individual/pub1441541
Source
wos
Published In
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
Volume
38
Published Date